Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes

Cytotherapy

Volumn 18, Issue 12, 2016, Pages 1515-1524

  McLaughlin, Lauren P ^a   Lang, Haili ^a   Williams, Elizabeth ^a   Wright, Kaylor E ^a   Powell, Allison ^a   Cruz, Conrad R ^a   Colberg Poley, Anamaris M ^a   Barese, Cecilia ^a   Hanley, Patrick J ^a   Bollard, Catherine M ^a   Keller, Michael D ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

antiviral therapy; cytotoxic T lymphocytes; human parainfluenza; immunodeficiency; immunotherapy

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR; VIRAL PROTEIN; VIRUS ANTIGEN;

ADENOVIRIDAE; ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; BK VIRUS; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOTOXICITY; CYTOTOXICITY ASSAY; EPSTEIN BARR VIRUS; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; HUMAN PARAINFLUENZA VIRUS 3; INTERFERON PRODUCTION; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RESPIROVIRUS INFECTION; T LYMPHOCYTE; TH1 CELL; BIOLOGICAL THERAPY; CELL CULTURE; FLOW CYTOMETRY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; PROCEDURES; RESPIROVIRUS INFECTIONS;

ANTIGENS, VIRAL; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOPHENOTYPING; INTERFERON-GAMMA; LYMPHOCYTE COUNT; PARAINFLUENZA VIRUS 3, HUMAN; RESPIROVIRUS INFECTIONS;

EID: 84994234952     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.08.010     Document Type: Article

References (37)

1. [1] Henrickson, K.J., Parainfluenza viruses. Clin Microbiol Rev 16:2 (2003), 242–264.
2. [2] Weinberg, G.A., Hall, C.B., Iwane, M.K., Poehling, KA, Edwards, KM, Griffin, MR, et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 154:5 (2009), 694–699.
3. [3] Hutspardol, S., Essa, M., Richardson, S., Schechter, T, Ali, M, Krueger, J, et al. Significant transplantation-related mortality from respiratory virus infections within the first one hundred days in children after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21:10 (2015), 1802–1807.
4. [4] Chemaly, R.F., Shah, D.P., Boeckh, M.J., Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 59:Suppl. 5 (2014), S344–51.
5. [5] Lujan-Zilbermann, J., Benaim, E., Tong, X., Srivastava, D.K., Patrick, C.C., DeVincenzo, J.P., Respiratory virus infections in pediatric hematopoietic stem cell transplantation. Clin Infect Dis 33:7 (2001), 962–968.
6. [6] Nichols, W.G., Corey, L., Gooley, T., Davis, C., Boeckh, M., Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 98:3 (2001), 573–578.
7. [7] Lewis, V.A., Champlin, R., Englund, J., Couch, R., Goodrich, J.M., Rolston, K., et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 23:5 (1996), 1033–1037.
8. [8] Baxter, B.D., Couch, R.B., Greenberg, S.B., Kasel, J.A., Maintenance of viability and comparison of identification methods for influenza and other respiratory viruses of humans. J Clin Microbiol 6:1 (1977), 19–22.
9. [9] Fishaut, M., Tubergen, D., McIntosh, K., Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 96:2 (1980), 179–186.
10. [10] Englund, J.A., Karron, R.A., Cunningham, C.K., Larussa, P, Melvin, A, Yogev, R, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine 31:48 (2013), 5706–5712.
11. [11] Moscona, A., Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest 115:7 (2005), 1688–1698.
12. [12] Leen, A.M., Heslop, H.E., Brenner, M.K., Antiviral T-cell therapy. Immunol Rev 258:1 (2014), 12–29.
13. [13] Papadopoulou, A., Gerdemann, U., Katari, U.L., Tzannou, I, Liu, H, Martinez, C, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med, 6(242), 2014, 242ra83.
14. [14] Gerdemann, U., Katari, U.L., Papadopoulou, A., Keirnan, JM, Craddock, JA, Liu, H, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 21:11 (2013), 2113–2121.
15. [15] Leen, A.M., Christin, A., Myers, G.D., Liu, H, Cruz, CR, Hanley, PJ, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114:19 (2009), 4283–4292.
16. [16] Leen, A.M., Myers, G.D., Sili, U., Huls, MH, Weiss, H, Leung, KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12:10 (2006), 1160–1166.
17. [17] Koehne, G., Hasan, A., Doubrovina, E., Prockop, S, Tyler, E, Wasilewski, G, et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant 21:9 (2015), 1663–1678.
18. [18] O'Reilly, R.J., Small, T.N., Papadopoulos, E., Lucas, K., Lacerda, J., Koulova, L., Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 157 (1997), 195–216.
19. [19] Karron, R.A., Collins, P.L., Parainfluenza viruses. Knipe, D.M., Howley, P.M., (eds.) Fields virology, 2013, Lippincott Williams & Wilkins, Philadelphia, PA, 996–1023.
20. [20] Dave, V.P., Allan, J.E., Slobod, K.S., Smith, FS, Ryan, KW, Takimoto, T, et al. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells. Virology 199:2 (1994), 376–383.
21. [21] Gerdemann, U., Keirnan, J.M., Katari, U.L., Yanagisawa, R, Christin, AS, Huye, LE, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 20:8 (2012), 1622–1632.
22. [22] Stokes, A., Tierney, E.L., Murphy, B.R., Hall, S.L., The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain. Virus Res 25:1–2 (1992), 91–103.
23. [23] Naik, S., Nicholas, S.K., Martinez, C.A., Leen, AM, Hanley, PJ, Gottschalk, SM, et al. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 137:5 (2016), 1498–1505.
24. [24] Hanley, P.J., Keller, M.D., Martin Manso, M., Matinez, C., Leung, K., Cruz, C., et al. A phase 1 perspective: multivirus-specific T-cells from both cord blood and bone marrow transplant donors. Cytotherapy, 18(6), 2016, S8.
25. [25] Ma, C.K., Blyth, E., Clancy, L., Simms, R, Burgess, J, Brown, R, et al. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation. Cytotherapy 17:10 (2015), 1406–1420.
26. [26] Blyth, E., Clancy, L., Simms, R., Ma, CK, Burgess, J, Deo, S, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 121:18 (2013), 3745–3758.
27. [27] Micklethwaite, K.P., Clancy, L., Sandher, U., Hansen, AM, Blyth, E, Antonenas, V, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 112:10 (2008), 3974–3981.
28. [28] Lehners, N., Tabatabai, J., Prifert, C., Wedde, M, Puthenparambil, J, Weissbrich, B, et al. Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders. PLoS ONE, 11(2), 2016 e0148258.
29. [29] de Lima, C.R., Mirandolli, T.B., Carneiro, L.C., Tusset, C, Romer, CM, Andreolla, HF, et al. Prolonged respiratory viral shedding in transplant patients. Transpl Infect Dis 16:1 (2014), 165–169.
30. [30] Goya, S., Mistchenko, A.S., Viegas, M., Phylogenetic and molecular analyses of human parainfluenza type 3 virus in Buenos Aires, Argentina, between 2009 and 2013: The emergence of new genetic lineages. Infect Genet Evol 39 (2016), 85–91.
31. [31] Mizuta, K., Tsukagoshi, H., Ikeda, T., Aoki, Y, Abiko, C, Itagaki, T, et al. Molecular evolution of the haemagglutinin-neuraminidase gene in human parainfluenza virus type 3 isolates from children with acute respiratory illness in Yamagata prefecture, Japan. J Med Microbiol 63:Pt 4 (2014), 570–577.
32. [32] Betts, M.R., Nason, M.C., West, S.M., De Rosa, SC, Migueles, SA, Abraham, J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:12 (2006), 4781–4789.
33. [33] Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, SK, Sixbey, JW, Gan, Y, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:5 (1998), 1549–1555.
34. [34] Feuchtinger, T., Richard, C., Joachim, S., Scheible, MH, Schumm, M, Hamprecht, K, et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 31:2 (2008), 199–206.
35. [35] Leen, A.M., Christin, A., Khalil, M., Weiss, H, Gee, AP, Brenner, MK, et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82:1 (2008), 546–554.
36. [36] Einsele, H., Roosnek, E., Rufer, N., Sinzger, C., Riegler, S., Löffler, J., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:11 (2002), 3916–3922.
37. [37] Busch, D.H., Frassle, S.P., Sommermeyer, D., Buchholz, V.R., Riddell, S.R., Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol 28:1 (2016), 28–34.